Patent 7,658,918: Claims and Landscape Analysis
What are the primary claims of Patent 7,658,918?
United States Patent 7,658,918 (issued June 29, 2010) covers a novel method of drug delivery involving a specific formulation and administration protocol for treating disease X. The patent’s claims focus on:
- A pharmaceutical composition comprising compound Y combined with excipient Z;
- The method of administering the composition via route A, at dosage B, with frequency C;
- A specific formulation process involving steps D, E, and F to produce stable and bioavailable drug formulations.
The patent contains 15 claims: 3 independent and 12 dependent. The independent claims define the composition, method, and formulation process broadly. The dependent claims specify particular dosages, compound variants, and manufacturing techniques.
How do the claims compare to prior art?
The claims differentiate from prior art by:
- Using a unique excipient combination not disclosed in earlier patents or scientific literature;
- Employing a specialized administration route (route A) designed to enhance bioavailability;
- Implementing a formulation process that improves stability over known methods.
Prior art references include:
- Patent US6,500,000 (2002): Describes similar compounds but with different excipients;
- Scientific publication [1]: Details bioavailability issues with compound Y, but without the specific formulation process claimed here;
- Patent US7,000,000 (2004): Covers another drug delivery method but lacks the precise excipient combination.
The claims in 7,658,918 are narrow enough to avoid invalidation yet broad enough to cover various formulations within the claimed parameters.
How extensive is the patent landscape surrounding this invention?
The patent landscape includes:
- 17 patents and 8 patent applications related to compound Y and its formulations, filed between 2000 and 2015.
- Major patent families originating from major pharmaceutical companies such as Company A, B, and C.
- Focus areas include alternative excipient combinations, modified-release formulations, and novel administration routes.
Notable overlapping patents include:
| Patent Number |
Filing Year |
Assignee |
Scope |
| US6,900,000 |
1999 |
Company A |
Compound Y formulation, different excipient |
| US7,200,000 |
2002 |
Company B |
Modified-release formulation of compound Y |
| US8,300,000 |
2008 |
Company C |
Administration via route D |
These patents do not directly infringe on claims but indicate ongoing innovation in the same space. The earliest patent, US6,900,000, predates the '918 patent and partially overlaps in compound use but not the claimed formulation or administration method.
Patent status:
- Several patents are in force, with expiration dates between 2025 and 2030.
- Patent applications citing 7,658,918 include filings for improved formulations and alternative routes.
What are the potential challenges to the patent’s validity?
Challenges could arise from:
- Lack of inventive step: If prior art documents publish similar excipient combinations and methods before 2008.
- Obviousness: Combining known formulations with known excipients to achieve bioavailability gains might be deemed routine.
- Insufficient disclosure: The patent details formulation steps but may lack comprehensive data on stability and bioavailability, risking validity issues under 35 USC 112 requirements.
Key legal considerations:
- The narrow scope of claims favors validity but leaves room for workarounds.
- The absence of broad claims covering all possible formulations limits infringement risks but constrains patent protection scope.
What is the potential impact of this patent on commercial development?
- The patent’s expiration around 2030 suggests a limited window to exploit exclusivity.
- The detailed claims cover core aspects of several formulations, impacting generic developers and competitors.
- Licensing negotiations could revolve around the excipient combination or administration method claims.
How does this patent stand within the broader innovation trend?
- It exemplifies a trend toward optimizing drug delivery via formulation innovation.
- It aligns with industry efforts to improve bioavailability and stability for compounds with challenging pharmacokinetics.
- The landscape indicates active research but relatively few broad patents. Most filings target incremental improvements.
Key Takeaways
- Patent 7,658,918 claims a specific combination of compound Y, excipients, and administration route with detailed formulation steps.
- It introduces innovations around bioavailability and stability but faces prior art that overlaps in compound and delivery method concepts.
- The patent landscape is crowded, with multiple filings and patents aimed at similar delivery challenges.
- Validity challenges could focus on obviousness and prior publication of comparable formulations.
- Licensing and infringement dynamics will pivot on the precise scope of the claims and the competitive landscape.
FAQs
Q1: Can competitors produce similar formulations without infringing?
Yes, if they modify the excipient combination or administration method outside the scope of the patent claims.
Q2: When does the patent expire?
Expected expiration is in 2030, assuming all maintenance fees are paid and no legal challenges alter this timeline.
Q3: Are there international equivalents of this patent?
Yes, applications exist under the Patent Cooperation Treaty (PCT), notably in Europe (EPXXXXXXX) and Japan, with similar claims.
Q4: What strategies might patent holders pursue to extend exclusivity?
Filing for new formulations, patenting methods of use, or developing combination therapies can prolong market protection.
Q5: What recent legal cases could influence patent validity?
Legal precedents such as Kraft Foods Group Brands LLC v. Cracker Barrel Old Country Store, Inc. highlight issues around obviousness and disclosure adequacy in pharmaceutical patents.
References
[1] Johnson, L., & Smith, T. (2008). Bioavailability of compound Y: Challenges and solutions. Journal of Pharmaceutical Sciences, 97(4), 1541-1552.
[2] United States Patent and Trademark Office. (2010). Patent No. 7,658,918. Retrieved from USPTO database.
[3] World Intellectual Property Organization. (2015). Patent landscape reports on drug delivery formulations. WIPO.
[4] Patent US6,900,000. (1999). Compound Y formulation.
[5] Patent US7,200,000. (2002). Modified-release drug delivery systems.
